Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues

Qian Guo, Wei Tang, Yoshinori Inagaki, Yutaka Midorikawa, Norihiro Kokudo, Yasuhiro Sugawara, Munehiro Nakata, Toshiro Konishi, Hirokazu Nagawa, Masatoshi Makuuchi

AIM: To assess subcellular localization of KL-6 mucin and its clinicopathological significance in colorectal carcinoma as well as metastatic lymph node and liver tissues.

METHODS: Colorectal carcinoma tissues as well as metastatic lymph node and liver tissues were collected from 82 patients who underwent colorectomy or hepatectomy. Tissues were subjected to immunohistochemical analysis using KL-6 antibody.

RESULTS: Of the 82 colorectal carcinoma patients, 6 showed no staining, 29 showed positive staining only in the apical membrane, and 47 showed positive staining in the circumferential membrane and/or cytoplasm. Positive staining was not observed in non-cancerous colorectal epithelial cells surrounding the tumor tissues. The five-year survival rate was significantly lower in cases showing positive staining in the circumferential membrane and/or cytoplasm (63.0%) than those showing positive staining only in the apical membrane (85.7%) and those showing no staining (100%). Statistical analysis between clinicopathological factors and subcellular localization of KL-6 mucin showed that KL-6 localization in the circumferential membrane and/or cytoplasm was significantly associated with the presence of venous invasion ($P = 0.0003$), lymphatic invasion ($P < 0.0001$), lymph node metastasis ($P < 0.0001$), liver metastasis ($P = 0.058$), and advanced histological stage ($P < 0.0001$). Positive staining was observed in all metastatic lesions tested as well as in the primary colorectal carcinoma tissues.

CONCLUSION: The subcellular staining pattern of KL-6 in colorectal adenocarcinoma may be an important indicator for unfavorable behaviors such as lymph node and liver metastasis, as well as for the prognosis of patients.

© 2006 The WJG Press. All rights reserved.

Key words: KL-6 mucin; Colorectal carcinoma; Metastasis; Prognosis; Immunohistochemistry

Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, Nakata M, Konishi T, Nagawa H, Makuuchi M. Clinical significance of subcellular localization of KL-6mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol 2006; 12(1): 54-59

http://www.wjgnet.com/1007-9327/12/54.asp

INTRODUCTION

MUC1, a transmembrane glycoprotein\(^{[1,2]}\), has been detected in various cancer cell lines and secretory epithelial cells lining the respiratory, reproductive, and gastrointestinal tracts\(^{[3-9]}\). It has been suggested that MUC1 may influence cell-to-cell adhesion, diminish the immune response, and be involved in intracellular signaling\(^{[7,8]}\). In carcinoma cells, it has been reported that high levels of MUC1 expression correlate with the invasive characteristic of tumors\(^{[9,10]}\). Our latest study has also shown that aberrant expression of MUC1, which was detected by KL-6 antibody, is associated with cancer progression in the carcinoma of the ampulla of Vater\(^{[11,12]}\).

In normal epithelium, MUC1 is predominantly present on the apical surface of the epithelial cells\(^{[13,14]}\). Recently, it has been reported that, in breast carcinoma, MUC1 is expressed not only on the apical surface but also on...
circumferential and basal membranes and in the cytoplasm of the carcinoma cells\[^{15,16}\]. Furthermore, this aberrant localization of MUC1 has been reported to be associated with worse prognosis for the patient\[^{17}\]. These findings suggest that subcellular observation of MUC1 expression in carcinoma cells is likely important for understanding the function of MUC1 and improving the prediction of prognosis. However, little is known about the clinical significance of subcellular localization of KL-6 mucin in other carcinomas.

In this study, we focused on subcellular localization of MUC1 in colorectal carcinoma as well as in the metastatic lymph nodes and liver tissue. MUC1 expression was immunohistochemically detected using KL-6 antibody, which recognizes the sialylated oligosaccharide moiety of MUC1 as a part of an epitope\[^{18}\]. In colorectal carcinoma tissues, it has been suggested that the expression of KL-6 mucin is associated with tumor aggressiveness\[^{19,20}\]. However, the subcellular localization and physiological function of KL-6 mucin in colorectal carcinoma have remained unknown. In this paper, we report that aberrant subcellular expression of KL-6 mucin in the circumferential membrane and/or cytoplasm is associated with lymph node and liver metastases and worse prognosis in colorectal carcinoma.

**MATERIALS AND METHODS**

**Patients**

Colorectal carcinoma tissues were collected from 82 consecutive patients (55 males and 27 females; 64.5 ± 11.4 years, mean ± SD) with a single primary colorectal adenocarcinoma who underwent surgical resection at the Department of Surgery, Graduate School of Medicine, the University of Tokyo, between January 1991 and December 1992. For all cases with lymph node and liver metastasis, whole specimens of resected lymph nodes and metastatic liver tissues were collected from 36 and 7 patients, respectively, in the study group. All specimens were classified according to Japanese Classification of Colorectal Carcinoma by the Japanese Society for Cancer of the Colon and Rectum\[^{20}\], including the status of lymph node and liver metastasis at the time of surgical intervention and the depth of invasion (m, invasion of mucosa; sm, invasion of submucosa; mp, invasion of muscularis propria; ss, invasion of subserosa or subadventitia; se, invasion of serosa or adventitia; and si, invasion of adjacent structures).

**Immunohistochemical staining**

The immunohistochemical staining approach matched that of previous studies\[^{14}\]. Briefly, 4 \(\mu\)m-thick sections were cut from archival formalin-fixed paraffin-embedded tissue blocks, deparaffinized, and dehydrated using a graded series of ethanol solutions. Endogenous peroxidase activity was halted through administration of 3 mL/L hydrogen peroxide/methanol for 30 min. The slides were rinsed with phosphate-buffered saline and then blocked with normal goat serum for 30 min at room temperature. The sections were then incubated with a KL-6 monoclonal antibody solution (1:200 dilution; Eisai, Tokyo, Japan) for 60 min at room temperature. After the sections were incubated with biotinylated secondary antibody for 60 min, bound biotinylated antibody was then tested by the biotin-streptavidin-peroxidase complex method following the manufacturer's instructions (Histofine SAB-PO kit; Nichirei, Tokyo, Japan). 3,3'-Diaminobenzidine was used as the chromogen, and hematoxylin was used as a counterstain. The negative control sections were treated by omitting the primary antibody to monitor background staining.

**Evaluation of immunohistochemically stained carcinomas**

Overall staining was evaluated in carcinoma cells observed in 10 random microscopic fields, or in the entire area if the tissue sample comprised less than 10 fields. Subcellular staining patterns were recorded by judging the apical membrane, circumferential membrane, and cytoplasm as described elsewhere\[^{17}\]. Three investigators (Q.G., W.T., and N.K.) separately judged the staining characteristics, and the discrepancies were resolved through mutual observation and discussion of the microscopic fields.

**Statistical analysis**

The \(\chi^2\)-test was used to evaluate the relationship between staining pattern and clinicopathological parameters. Survival curves were calculated using the Kaplan-Meier method and compared with the results of the log-rank test. Two patients (one in the no-staining group, another in the apical membrane staining group) were excluded from the data analysis for survival because the cause of death for these patients was not colorectal cancer. \(P < 0.05\) was considered statistically significant. Statview 5.0J (Abacus Concepts, Berkeley, CA, USA) statistical software was used for data analyses.

**RESULTS**

**Subcellular localization of KL-6 mucin**

Among the 82 cases of colorectal carcinoma, 76 cases showed positive staining of KL-6 mucin. As shown in Figure 1, there was a considerable heterogeneity in the subcellular localization of KL-6 mucin. Staining was observed in either the apical or circumferential membrane (Figures 1A and 1B). Some cases showed positive staining in the cytoplasm in addition to the membranous region (Figures 1C and 1D). The number of cases showing the respective subcellular staining patterns are summarized in Table 1. It is notable that cytoplasmic staining tended to be accompanied by positive staining in the circumferential membrane (37/45, 82%) rather than in the apical membrane (8/45, 18%). Positive staining was not observed in non-cancerous colorectal epithelial cells in any case of this study (data not shown).

**Relationship between survival and subcellular localization of KL-6 mucin**

The five-year survival rate was 85.7% for cases showing positive staining only in the apical membrane (\(n = 28\)), 61.5% for cases showing positive staining in the circumferential membrane (\(n = 39\)), and 64.4% for cases showing positive staining in cytoplasm (\(n = 45\)) (data...
There were significant differences between the cases showing positive staining only in the apical membrane and the cases showing positive staining in the circumferential membrane ($P = 0.021$), and between the cases showing positive staining only in the apical membrane and the cases showing positive staining in cytoplasm ($P = 0.033$). On the other hand, the five-year survival rate was 100% for the cases showing no staining ($n = 5$). These results suggested that a subcellular KL-6 expression profile was associated with survival, and that cases showing positive staining in the circumferential membrane and/or cytoplasm showed worse prognosis.

As described above, cytoplasmic staining tended to be accompanied with positive staining of the circumferential membrane. Therefore, we classified the cases into the following three groups according to their subcellular staining profile: group N, negative ($n = 6$); group A, positive only in the apical membrane ($n = 29$); and group C, positive in the circumferential membrane and/or cytoplasm ($n = 47$) (Table 1).

| Group $^1$ | Apical membrane | Circumferential membrane | Cytoplasm | $n$ |
|------------|-----------------|---------------------------|-----------|-----|
| N          | Negative        | Negative                  | Negative  | 6   |
| A          | Positive        | Negative                  | Negative  | 29  |
| C          | Positive        | Negative                  | Positive  | 8   |
| C          | Negative        | Positive                  | Negative  | 2   |
| C          | Negative        | Positive                  | Positive  | 37  |

$^1$Patient groups N, A, and C were categorized according to the subcellular expression profile of KL-6 mucin (see text).

Relationship between clinicopathological factors and subcellular localization of KL-6 mucin

The relationship between clinicopathological factors and subcellular KL-6 mucin staining of the colorectal adenocarcinomas is summarized in Table 2. Positive staining in the circumferential membrane and/or cytoplasm was significantly associated with the presence of venous invasion, lymphatic invasion, and lymph node metastasis. This subcellular staining characteristic was also associated with the progression of the depth of invasion and histological stage (Table 2).

Notably, all cases having lymph node ($n = 36$) or liver metastasis ($n = 7$) showed positive staining in the circumferential membrane and/or cytoplasm. This suggested that aberrant subcellular expression of KL-6 mucin in the circumferential
expression of KL-6 mucin might facilitate detachment of tumor cells from the primary growth to extracellular matrix interactions, thereby facilitating metastatic potentiality, and the prognosis of colorectal adenocarcinoma have primarily focused on the tandem-repeat domain, and suggested that tumor cells expressing high levels of MUC1 may have increased invasive and metastatic potential. However, little is known about the detailed clinicopathological relationship among expression profile of MUC1, metastatic potentiality, and the prognosis for colorectal adenocarcinoma. On the other hand, although the processing of the full length MUC1 core proteins is similar in both normal and tumor cells, they have a remarkable diversity in oligosaccharide moieties. Therefore, we targeted KL-6 mucin, a type of MUC1 bearing sialylated oligosaccharide recognized by KL-6 antibody. Since sialylation of tumor cell glycoconjugates is thought to contribute to tumor progression and metastasis, targeting KL-6 mucin bearing sialylated oligosaccharide seems to be a reasonable strategy.

In our preliminary study, KL-6 mucin was observed in carcinoma cells but not in the surrounding normal cells. However, classification of KL-6 staining evaluated by overall expression level did not show significant relationships between the expression level of KL-6 mucin, metastasis, and patient’s prognosis (data not shown). Recently, some reports on breast carcinoma have suggested a significant relationship between metastasis and subcellular location of MUC1 rather than its overall expression level, which led us to focus on the subcellular location of KL-6 mucin in colorectal carcinoma.

In the present study, the circumferential and/or cytoplasmic expression of KL-6 mucin was significantly correlated with lymph node metastasis in colorectal adenocarcinomas (Table 2). In addition, this aberrant localization of KL-6 mucin was likely to participate also in liver metastasis, since all cases having liver metastasis (n = 7) showed positive staining in the circumferential membrane and/or cytoplasm (Table 2). It is known that normal epithelial cells release a tailless, soluble form of MUC1 which targets exclusively the apical membrane in tissues. However, in carcinoma cells with aberrant overexpression of KL-6 mucin, the apical polarization is lost, resulting in aberrant localization of MUC1 over the entire cell membrane and in the cytoplasm. It has been proposed that MUC1 mediates anti-adhesion activity by interfering with cell-to-cell and/or cell-to-extracellular matrix interactions, thereby facilitating detachment of tumor cells from the primary growth. This is likely true of KL-6 mucin in colorectal adenocarcinoma, since a high frequency of metastasis was observed in cases showing any aberrant localization of KL-6 mucin (Table 2). This aberrant subcellular expression of KL-6 mucin might facilitate detachment of tumor cells from the primary growth, resulting in an increased ability of the tumor cells to metastasize.

It is notable that all the cases tested showed positive staining in metastatic lesions as well as in the primary colorectal carcinoma tissues. Interestingly, in some cases presenting lymph node or liver metastasis, aberrant subcellular localization of KL-6 was observed in only circumferential localization of KL-6 mucin was likely to participate also in liver metastasis, since all cases having liver metastasis (n = 7) showed positive staining in the circumferential membrane and/or cytoplasm (Table 2). It is known that normal epithelial cells release a tailless, soluble form of MUC1 which targets exclusively the apical membrane in tissues. However, in carcinoma cells with aberrant overexpression of KL-6 mucin, the apical polarization is lost, resulting in aberrant localization of MUC1 over the entire cell membrane and in the cytoplasm. It has been proposed that MUC1 mediates anti-adhesion activity by interfering with cell-to-cell and/or cell-to-extracellular matrix interactions, thereby facilitating detachment of tumor cells from the primary growth. This is likely true of KL-6 mucin in colorectal adenocarcinoma, since a high frequency of metastasis was observed in cases showing any aberrant localization of KL-6 mucin (Table 2). This aberrant subcellular expression of KL-6 mucin might facilitate detachment of tumor cells from the primary growth, resulting in an increased ability of the tumor cells to metastasize.

It is notable that all the cases tested showed positive staining in metastatic lesions as well as in the primary colorectal carcinoma tissues. Interestingly, in some cases presenting lymph node or liver metastasis, aberrant subcellular localization of KL-6 was observed in only circumferential localization of KL-6 mucin was likely to participate also in liver metastasis, since all cases having liver metastasis (n = 7) showed positive staining in the circumferential membrane and/or cytoplasm (Table 2). It is known that normal epithelial cells release a tailless, soluble form of MUC1 which targets exclusively the apical membrane in tissues. However, in carcinoma cells with aberrant overexpression of KL-6 mucin, the apical polarization is lost, resulting in aberrant localization of MUC1 over the entire cell membrane and in the cytoplasm. It has been proposed that MUC1 mediates anti-adhesion activity by interfering with cell-to-cell and/or cell-to-extracellular matrix interactions, thereby facilitating detachment of tumor cells from the primary growth. This is likely true of KL-6 mucin in colorectal adenocarcinoma, since a high frequency of metastasis was observed in cases showing any aberrant localization of KL-6 mucin (Table 2). This aberrant subcellular expression of KL-6 mucin might facilitate detachment of tumor cells from the primary growth, resulting in an increased ability of the tumor cells to metastasize.

It is notable that all the cases tested showed positive staining in metastatic lesions as well as in the primary colorectal carcinoma tissues. Interestingly, in some cases presenting lymph node or liver metastasis, aberrant subcellular localization of KL-6 was observed in only circumferential localization of KL-6 mucin was likely to participate also in liver metastasis, since all cases having liver metastasis (n = 7) showed positive staining in the circumferential membrane and/or cytoplasm (Table 2). It is known that normal epithelial cells release a tailless, soluble form of MUC1 which targets exclusively the apical membrane in tissues. However, in carcinoma cells with aberrant overexpression of KL-6 mucin, the apical polarization is lost, resulting in aberrant localization of MUC1 over the entire cell membrane and in the cytoplasm. It has been proposed that MUC1 mediates anti-adhesion activity by interfering with cell-to-cell and/or cell-to-extracellular matrix interactions, thereby facilitating detachment of tumor cells from the primary growth. This is likely true of KL-6 mucin in colorectal adenocarcinoma, since a high frequency of metastasis was observed in cases showing any aberrant localization of KL-6 mucin (Table 2). This aberrant subcellular expression of KL-6 mucin might facilitate detachment of tumor cells from the primary growth, resulting in an increased ability of the tumor cells to metastasize.

It is notable that all the cases tested showed positive staining in metastatic lesions as well as in the primary colorectal carcinoma tissues. Interestingly, in some cases presenting lymph node or liver metastasis, aberrant subcellular localization of KL-6 was observed in only
apical staining of KL-6 mucin. These data suggest that the patients expressing MUC1 in the non-apical membranes and expression of KL-6 mucin in the circumferential mucin plays a crucial role in determining disease outcome for the prediction of a patient's prognosis in colorectal adenocarcinoma.

Further investigation is needed to understand the role of KL-6 expression in metastatic events of colorectal carcinoma.

Some studies have reported that, in breast carcinoma, patients expressing MUC1 in the non-apical membranes show worse prognosis than those expressing MUC1 in the apical membrane. Our observation also showed that there was a significant relationship between subcellular location of KL-6 and prognosis in colorectal adenocarcinoma (Figure 2; P = 0.029). The five-year survival rates for the cases showing positive membranous and/or cytoplasmic staining did not present with metastases. Further investigation is needed to understand the role of KL-6 expression in metastatic events of colorectal adenocarcinoma.

In conclusion, subcellular localization of KL-6 mucin plays a crucial role in determining disease outcome and expression of KL-6 mucin in the circumferential membrane and/or cytoplasm is an important indicator for lymph node and liver metastases as well as the prognosis of patients with colorectal adenocarcinoma.

REFERENCES

1. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990; 265: 15286-15293
2. Lan MS, Batra SK, Qi WN, Metzgar RS, Hollingsworth MA. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem 1990; 265: 15294-15299
3. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol 1995; 57: 607-634
4. Hey NA, Graham RA, Seif MW, Aplin JD. The polymorphic epithelial mucin MUC1 in human endometrium is regulated with maximal expression in the implantation phase. J Clin Endocrinol Metab 1994; 78: 337-342
5. Hilkens J, Buijs F. Biosynthesis of MAM-6, an epithelial sialomucin. Evidence for involvement of a rare proteolytic cleavage step in the endoplasmic reticulum. J Biol Chem 1988; 263: 4215-4222
6. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004; 4: 45-60
7. Meerzaman D, Xing PX, Kim KC. Construction and characterization of a chimeric receptor containing the cytoplasmic domain of MUC1 mucin. Am J Physiol Lung Cell Mol Physiol 2000; 278: L625-L629
8. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998; 4: 43-49
9. Nakamori S, Ota DM, Cleary KR, Shiratori K, Irimura T. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 1994; 106: 353-361
10. Hiraga Y, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiya G, Shimamoto F, Kohno N. Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 1998; 55: 307-319
11. Kashiwagi H, Kijima H, Dowaki S, Ohtani Y, Tobita K, Tsukui M, Tanaka Y, Matsuabayasi H, Tsuchida T, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, Tajima T, Makuchii H. DF3 expression in human gallbladder carcinoma: significance for lymphatic invasion. Int J Oncol 2000; 16: 455-459
12. Zhang HK, Zhang QM, Zhao TH, Li YY, Yi YF. Expression of mucins and E-cadherin in gastric carcinoma and their clinical significance. World J Gastroenterol 2004; 10: 3044-3047
13. Lüttges J, Feyerabend B, Buchelt T, Pacena M, Kloppep G. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 2002; 26: 466-471
14. Tang W, Inagaki Y, Kokudo N, Guo Q, Seyama Y, Nakata M, Imamura H, Sano K, Sugawara Y, Makuchi M. KL-6 mucin expression in carcinoma of the ampulla of Vater: association with cancer progression. World J Gastroenterol 2005; 11: 5450-5454
15. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984; 3: 223-232
16. Perry L, Hayes DF, Mainmonis P, Abe M, O’Hara C, Kufe DW. Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res 1992; 52: 2563-2568
17. Rahn JJ, Dabagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the
literature. *Cancer* 2001; **91**: 1973-1982

18 **Kohno N**, Akiyama M, Kyozumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. *Jpn J Clin Oncol* 1988; **18**: 203-216

19 **Aoki R**, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F, Kohno N. MUC-1 expression as a predictor of the curative endoscopic treatment of submucosally invasive colorectal carcinoma. *Dis Colon Rectum* 1998; **41**: 1262-1272

20 Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal carcinoma. 1st English ed. Tokyo: Kanehara, 1997: 4-82

21 **Julian J**, Carson DD. Formation of MUC1 metabolic complex is conserved in tumor-derived and normal epithelial cells. *Biochem. Biophys. Res. Commun.* 2002; **293**: 1183-1190

22 **Osako M**, Yonezawa S, Siddiki B, Huang J, Ho JJ, Kim YS, Sato E. Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. *Cancer* 1993; **71**: 2191-2199

23 **Ikeda Y**, Mori M, Kajiyama K, Haraguchi Y, Sasaki O, Sugimachi K. Immunohistochemical expression of sialyl Tn, sialyl Lewis a, sialyl Lewis a-b, and sialyl Lewis x in primary tumor and metastatic lymph nodes in human gastric cancer. *J Surg Oncol* 1996; **62**: 171-176

24 **Li XW**, Ding YQ, Cai JJ, Yang SQ, An LB, Qiao DF. Studies on mechanism of Sialyl Lewis-X antigen in liver metastases of human colorectal carcinoma. *World J Gastroenterol.* 2001; **7**: 425-430

25 **Tang W**, Mafune K, Nakata M, Konishi T, Kojima N, Mizuochi T, Makuuchi M. Association of histochemical expression of Maackia amurensis leukoagglutinin-positive glycoconjugates with behaviour of human gastric cancer. *Histopathology* 2003; **42**: 239-245

26 **Tang W**, Guo Q, Usuda M, Kokudo N, Seyama Y, Minagawa M, Sugawara Y, Nakata M, Kojima N, Makuuchi M. Histochemical expression of sialylglycoconjugates in carcinoma of the papilla of Vater. *Hepatogastroenterology* 2005; **52**: 67-71

27 **Kohlgraf KG**, Gawron AJ, Higashi M, Meza JL, Burdick MD, Kitajima S, Kelly DL, Caffrey TC, Hollingsworth MA. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. *Cancer Res* 2003; **63**: 5011-5020

28 **Ligtenberg MJ**, Buijs F, Vos HL, Hilken J. Suppression of cellular aggregation by high levels of episialin. *Cancer Res* 1992; **52**: 2318-2324

29 **Wesseling J**, van der Valk SW, Vos HL, Sonnenberg A, Hilken J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. *J Cell Biol* 1995; **129**: 255-265

30 **Hayes DF**, Mesa-Tejada R, Papsidero LD, Croghan GA, Korzun AH, Norton L, Wood W, Strauchen JA, Grimes M, Weiss RB. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. *J Clin Oncol* 1991; **9**: 1113-1123

S- Editor Kumar M and Guo SY   L- Editor Elsevier HK   E-Editor Li HY